Please use this identifier to cite or link to this item:
https://doi.org/10.3390/cancers15102733
Title: | Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer | Authors: | Huang, Yiqing Zhao, Joseph J Soon, Yu Yang Kee, Adrian Tay, Sen Hee Aminkeng, Folefac Ang, Yvonne Wong, Alvin SC Bharwani, Lavina D Goh, Boon Cher Soo, Ross A |
Keywords: | Science & Technology Life Sciences & Biomedicine Oncology primary resistance immune checkpoint inhibitor non-small-cell lung cancer TO-LYMPHOCYTE RATIO OPEN-LABEL ACQUIRED-RESISTANCE 1ST-LINE NIVOLUMAB SEX-DIFFERENCES PHASE-3 CHEMOTHERAPY MULTICENTER DOCETAXEL PEMBROLIZUMAB |
Issue Date: | 12-May-2023 | Publisher: | MDPI | Citation: | Huang, Yiqing, Zhao, Joseph J, Soon, Yu Yang, Kee, Adrian, Tay, Sen Hee, Aminkeng, Folefac, Ang, Yvonne, Wong, Alvin SC, Bharwani, Lavina D, Goh, Boon Cher, Soo, Ross A (2023-05-12). Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer. CANCERS 15 (10). ScholarBank@NUS Repository. https://doi.org/10.3390/cancers15102733 | Abstract: | Introduction: Primary resistance to immune checkpoint inhibitors (ICI) is observed in routine clinical practice. We sought to determine factors predictive of primary resistance to ICI monotherapy, defined by the Society for Immunotherapy of Cancer (SITC) as progression within 6 months of ICI treatment with patients receiving at least 6 weeks of ICI monotherapy, in patients with advanced non-small-cell lung cancer (NSCLC). Method: Patients with stage IV NSCLC treated with at least 6 weeks of single-agent ICI at two tertiary hospitals in Singapore were included. A multivariate logistic regression model was utilised to elucidate factors predictive of primary resistance to ICI. Results: Of the 108 eligible patients, 59 (54.6%) experienced primary resistance. The majority were male (65.7%), smokers (66.3%), Chinese (79.6%), had adenocarcinoma (76.9%), received Pembrolizumab (55.6%) and received immunotherapy treatment in the later line setting (≥2 lines) (61.1%). Female gender (aOR = 3.16, p = 0.041), a sixth-week neutrophil-to-lymphocyte ratio (NLR) of ≥3) (aOR = 3.454, p = 0.037) and a later line of immunotherapy treatment (≥2 lines) (aOR = 2.676, p = 0.040) were factors predictive of primary resistance to ICI monotherapy in patients with advanced NSCLC. Conclusions: Using SITC criteria, an elevated NLR (≥3) at 6 weeks, female gender and a later line of immunotherapy treatment (≥2 lines) were predictive factors of developing primary resistance to ICI monotherapy in patients with advanced NSCLC. | Source Title: | CANCERS | URI: | https://scholarbank.nus.edu.sg/handle/10635/245745 | ISSN: | 2072-6694 | DOI: | 10.3390/cancers15102733 |
Appears in Collections: | Staff Publications Elements |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cance.pdf | 994.2 kB | Adobe PDF | OPEN | Published | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.